home / stock / sybx / sybx quote
Last: | $1.47 |
---|---|
Change Percent: | 0.68% |
Open: | $1.4501 |
Close: | $1.47 |
High: | $1.495 |
Low: | $1.4501 |
Volume: | 3,022 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.47 | $1.4501 | $1.47 | $1.495 | $1.4501 | 3,022 | 07-05-2024 |
$1.46 | $1.41 | $1.46 | $1.46 | $1.41 | 7,001 | 07-04-2024 |
$1.46 | $1.41 | $1.46 | $1.46 | $1.41 | 7,001 | 07-03-2024 |
$1.43 | $1.53 | $1.43 | $1.53 | $1.4101 | 13,951 | 07-02-2024 |
$1.49 | $1.53 | $1.49 | $1.55 | $1.48 | 9,842 | 07-01-2024 |
$1.5 | $1.53 | $1.5 | $1.545 | $1.37 | 79,360 | 06-28-2024 |
$1.55 | $1.51 | $1.55 | $1.55 | $1.495 | 25,406 | 06-27-2024 |
$1.52 | $1.535 | $1.52 | $1.57 | $1.5 | 6,729 | 06-26-2024 |
$1.55 | $1.49 | $1.55 | $1.55 | $1.47 | 45,888 | 06-25-2024 |
$1.52 | $1.4799 | $1.52 | $1.52 | $1.4799 | 4,725 | 06-24-2024 |
$1.49 | $1.52 | $1.49 | $1.54 | $1.45 | 39,237 | 06-21-2024 |
$1.53 | $1.55 | $1.53 | $1.58 | $1.35 | 68,956 | 06-20-2024 |
$1.59 | $1.57 | $1.59 | $1.59 | $1.52 | 32,202 | 06-19-2024 |
$1.59 | $1.57 | $1.59 | $1.59 | $1.52 | 32,202 | 06-18-2024 |
$1.59 | $1.63 | $1.59 | $1.63 | $1.58 | 5,944 | 06-17-2024 |
$1.6 | $1.61 | $1.6 | $1.63 | $1.56 | 5,205 | 06-14-2024 |
$1.62 | $1.64 | $1.62 | $1.65 | $1.56 | 40,482 | 06-13-2024 |
$1.6 | $1.58 | $1.6 | $1.63 | $1.56 | 8,170 | 06-12-2024 |
$1.62 | $1.59 | $1.62 | $1.62 | $1.5722 | 4,399 | 06-11-2024 |
$1.57 | $1.59 | $1.57 | $1.63 | $1.56 | 12,517 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the first quarter 2024 and provided a corporate update. In March 2024, t...
CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023. The Company...